These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 32406541)

  • 1. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
    Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M
    Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
    JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer.
    He WZ; Wang L; Yin CX; Yi JH; Jin YN; Jiang C; Guo GF; Xia LP
    Cancer Med; 2023 Mar; 12(6):6488-6498. PubMed ID: 36373163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study.
    Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X
    Front Oncol; 2020; 10():594125. PubMed ID: 33282742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
    Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y
    Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
    Kim RD; Kovari BP; Martinez M; Xie H; Sahin IH; Mehta R; Strosberg J; Imanirad I; Ghayouri M; Kim YC; Kim DW
    Eur J Cancer; 2022 Jul; 169():93-102. PubMed ID: 35526308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness.
    Xu YJ; Zhang P; Hu JL; Liang H; Zhu YY; Cui Y; Niu P; Xu M; Liu MY
    World J Gastrointest Oncol; 2022 Apr; 14(4):920-934. PubMed ID: 35582108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
    Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
    BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
    Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
    Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.
    Dai X; Ding W; He Y; Huang S; Liu Y; Wu T
    Front Oncol; 2023; 13():1227644. PubMed ID: 37681031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
    Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report.
    Yang Y; Xu L; Wang D; Hui B; Li X; Zhou Y; Chen X; Gu Y
    Immunotherapy; 2021 Nov; 13(16):1317-1323. PubMed ID: 34369830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
    Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
    Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases.
    Fakih M; Wang C; Sandhu J; Ye J; Egelston C; Li X
    Eur J Cancer; 2024 Jan; 196():113437. PubMed ID: 37980853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
    Fakih M; Raghav KPS; Chang DZ; Larson T; Cohn AL; Huyck TK; Cosgrove D; Fiorillo JA; Tam R; D'Adamo D; Sharma N; Brennan BJ; Wang YA; Coppieters S; Zebger-Gong H; Weispfenning A; Seidel H; Ploeger BA; Mueller U; Oliveira CSV; Paulson AS
    EClinicalMedicine; 2023 Apr; 58():101917. PubMed ID: 37090438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
    Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
    Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
    Saunders MP; Graham J; Cunningham D; Plummer R; Church D; Kerr R; Cook S; Zheng S; La Thangue N; Kerr D
    ESMO Open; 2022 Dec; 7(6):100594. PubMed ID: 36327756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argil├ęs G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.